Patents Represented by Attorney Walter H. Dreger
-
Patent number: 5677440Abstract: Conjugates of the type Z--X--L are described wherein Z is a solid phase matrix, X is a single amino acid or a polyamide of two or more amino acid residues, and L is a linker that is capable of linking between the amino terminus of X and a 3'-phosphate of a nucleotide. Conjugates may also be synthesized by assembling a polyamide on a solid support matrix, adding a suitable linker molecule, followed by synthesis of an oligonucleotide thereon. Methods for detecting specific polynucleotides with oligonucleotide-polyamide conjugates are also described.Type: GrantFiled: February 9, 1996Date of Patent: October 14, 1997Assignee: Howard Florey Institute of Experimental Physiology and MedicineInventors: Jim Haralambidis, Geoffrey William Tregear
-
Patent number: 5672805Abstract: The present invention provides non-human, transgenic animals for use as a model for the study of Alzheimer's Disease. The animals exhibit pathology associated with Alzheimer's Disease. The phenotype is conferred in the animals by the introduction of an amyloid-containing polypeptide fragment of amyloid precursor protein, through the introduction of the DNA into the germ and somatic cells of the animal by transgenic methods.Type: GrantFiled: July 18, 1991Date of Patent: September 30, 1997Assignee: The Regents of the University of CaliforniaInventor: Rachael L. Neve
-
Patent number: 5665362Abstract: A mutant virus for use as a vaccine, wherein the genome of the virus is defective in respect of a gene essential for the production of infectious virus. In one aspect the mutant virus is capable of protecting a susceptible species immunized therewith against infection by the corresponding wild-type virus. In another aspect, the mutant virus acts as a vector for an immunogenic protein derived from a pathogen and which is encoded by foreign DNA incorporated in the mutant virus. The mutant virus can be produced in a recombinant host cell which expresses a gene complementing the defect. The mutant virus is preferably infectious for the host to be protected, but the defective gene allows expression in the infected host of at least some of the vital genes, which can provoke a cell-mediated immune response.Type: GrantFiled: February 7, 1995Date of Patent: September 9, 1997Assignee: Cantab Pharmaceuticals Research LimitedInventors: Stephen Charles Inglis, Michael Edward Griffith Boursnell, Anthony Charles Minson
-
Patent number: 5663304Abstract: A composition is provided comprising about 0.1 to 15 mg/mL of a polypeptide in a buffer having a pH of about 7-12 comprising about 5-40% (v/v) of an alcoholic or polar aprotic solvent, about 0.2 to 3M of an alkaline earth, alkali metal, or ammonium salt, about 0.1 to 9M of a chaotropic agent, and about 0.01 to 15 .mu.M of a copper or manganese salt. The buffer is suitably used in a method for refolding improperly folded polypeptides.Type: GrantFiled: August 20, 1993Date of Patent: September 2, 1997Assignee: Genentech, Inc.Inventors: Stuart Builder, Roger Hart, Philip Lester, David Reifsnyder
-
Patent number: 5661122Abstract: Methods of enhancing myocardial contractility and cardiac performance in a mammal with congestive heart failure are disclosed. In a first method a mammal with congestive heart failure is treated by administering to the mammal an effective amount of a combination of growth hormone (GH) and insulin-like growth factor (IGF-I). A second method comprises administering to the mammal an effective amount of a combination of GH and IGF-I in the presence of an ACE inhibitor. This method results in enhancement of myocardial contractility and cardiac performance above the level achieved with ACE inhibition alone. Preferably the mammal is a human.Type: GrantFiled: August 2, 1994Date of Patent: August 26, 1997Assignee: Genentech, Inc.Inventors: Ross G. Clark, Hongkui Jin, Nicholas F. Paoni, Renhui Yang
-
Patent number: 5658762Abstract: DNA molecules, expression vectors, recombinant host cells and the process of preparing antigenized antibodies which have, inserted within their third complementarity determining regions, antigenic epitopes not found in immunoglobulin molecules are described.Type: GrantFiled: June 6, 1995Date of Patent: August 19, 1997Inventors: Maurizio Zanetti, Maurizio Sollazzo
-
Patent number: 5656096Abstract: A method for safely removing even a hazardous contaminant from a substrate surface without either precoating the contaminant or constantly flowing an inert gas thereover is disclosed. A pulsed source of light energy having an output spectrum including an infrared component and a visible component is directed upon the contaminant. The directed energy being sufficient in magnitude to carbonize or to decompose the contaminant. Preferably produced by a flashtube, the energy has a repetition rate ranging from about 0.1 to 12 pulses/second, and a peak energy per pulse exceeding about 3,700 Joules. The sound and/or sound level at the pulsed source of light energy may be monitored as a guide to varying the light source energy characteristics to best effect contaminant removal.Type: GrantFiled: January 26, 1995Date of Patent: August 12, 1997Assignee: Polygon Industries, Inc.Inventor: David C. Van Alstyne
-
Patent number: 5654258Abstract: A solid, water dispersible, storage-stable trifluralin formulation comprises trifluralin supported inside porous, finely divided carrier particles, optionally together with at least one compatible wetting agent and/or dispersant additive, wherein the trifluralin is in the orange polymorphic form and the particles of the formulation are size-stable.Type: GrantFiled: September 13, 1995Date of Patent: August 5, 1997Assignee: Daratech Pty. Ltd.Inventors: Darren James Park, Gottfried Lichti
-
Patent number: 5652110Abstract: The invention relates to monoclonal antibodies to the .alpha.v.beta.3 integrin receptor known to be expressed in large amounts on the surface of osteoclasts and accordingly, associated with bone resorption. The disclosed monoclonal antibodies are believed to recognize unique epitopes on .alpha.v.beta.3 and are useful in the treatment of conditions associated with excessive bone resorption and/or in the inhibition of tumor cell growth.Type: GrantFiled: May 2, 1995Date of Patent: July 29, 1997Assignee: Genentech, Inc.Inventors: Kyung Jin Kim, Michael A. Horton, Sarah C. Bodary, Anan Chuntharapai
-
Patent number: 5652109Abstract: The invention relates to monoclonal antibodies to the .alpha.v.beta.3 integrin receptor known to be expressed in large amounts on the surface of osteoclasts and accordingly, associated with bone resorption. The disclosed monoclonal antibodies are believed to recognize unique epitopes on .alpha.v.beta.3 and are useful in the treatment of conditions associated with excessive bone resorption and/or in the inhibition of tumor cell growth.Type: GrantFiled: May 2, 1995Date of Patent: July 29, 1997Assignee: Genentech, Inc.Inventors: Kyung Jin Kim, Michael A. Horton, Sarah C. Bodary, Anan Chuntharapai
-
Patent number: 5641650Abstract: This invention relates to the preparation and use of expression systems capable of producing heterologous polypeptides in halobacterial hosts.Type: GrantFiled: September 27, 1994Date of Patent: June 24, 1997Assignee: The Regents of the University of CaliforniaInventors: George J. Turner, Mary C. Betlach
-
Patent number: 5635601Abstract: The cDNA encoding a novel beta integrin subunit, called the beta-8 integrin subunit, has been isolated from rabbit and human tissue and sequenced. Provided herein is nucleic acid sequence of the beta-8 integrin subunit useful as a diagnostic and in the recombinant preparation of beta-8 integrin subunit and alpha-beta integrin complexes. The beta-8 integrin subunit is used in the preparation and purification of antibodies thereto, and in diagnostic assays.Type: GrantFiled: May 30, 1995Date of Patent: June 3, 1997Assignee: Genentech, Inc.Inventors: Matthew Moyle, John W. McLean
-
Patent number: 5624899Abstract: A novel hepatoma transmembrane kinase receptor ligand (Htk ligand) which binds to, and activates, the Htk receptor is disclosed. As examples, mouse and human Htk ligands have been identified in a variety of tissues using a soluble Htk-Fc fusion protein. The ligands have been cloned and sequenced. The invention also relates to nucleic acids encoding the ligand, methods for production and use of the ligand, and antibodies directed thereto.Type: GrantFiled: May 5, 1995Date of Patent: April 29, 1997Assignee: Genentech Inc.Inventors: Brian D. Bennett, William Matthews
-
Patent number: 5615979Abstract: A mine support bag comprises an inner fabric tube of selected length and selected circumference having an inner surface and outer surface. A first fabric sheet is laminated to the outer surface on the one side of the tube, the first fabric sheet having a width which is wider than half of the tube circumference. The first fabric sheet has longitudinal edges which run generally parallel with the length of the tube and extend beyond opposite lateral edges of the tube. A second fabric sheet is laminated to the opposite side of the tube, the second fabric sheet having a width which is wider than half of the tube circumference, the second fabric sheet having longitudinal edges which run generally parallel with the length of the tube and extend beyond opposite lateral edges of the tube. The respective lateral edges of the first and second sheets overlie each other and are laminated together.Type: GrantFiled: August 28, 1995Date of Patent: April 1, 1997Inventor: Fen-Fen Lin
-
Patent number: 5614487Abstract: The present document discloses the formation of imine adducts, preferably between a primary amine of a biologically active polypeptide and a reactive aldehyde group of a physiologically acceptable carrier. The imine adduct of human growth hormone and dextran is specifically described. These adducts serve to release the biologically active polypeptide via the reversible reaction in the formation of the imine adduct bond. These adducts have a surprising degree of stability that permits the use of the complex as a sustained release preparation. A key advantage of this technology is that after hydrolysis the complex releases the unmodified pharmaceutical. Thus, these adducts can be used as pharmaceutical compositions useful for the sustained release of the biologically active polypeptide over a predetermined, desired period of time.Type: GrantFiled: May 28, 1993Date of Patent: March 25, 1997Assignee: Genentech, Inc.Inventors: John E. Battersby, Ross G. Clark, William S. Hancock
-
Patent number: 5610134Abstract: Methods of enhancing myocardial contractility and cardiac performance in a mammal with congestive heart failure are disclosed. In a first method a mammal with congestive heart failure is treated by administering to the mammal an effective amount of a combination of growth hormone (GH) and insulin-like growth factor (IGF-I). A second method comprises administering to the mammal an effective amount of a combination of GH and IGF-I in the presence of an ACE inhibitor. This method results in enhancement of myocardial contractility and cardiac performance above the level achieved with ACE inhibition alone. Preferably the mammal is a human.Type: GrantFiled: November 3, 1994Date of Patent: March 11, 1997Assignee: Genentech, Inc.Inventors: Ross G. Clark, Hongkui Jin, Nicholas F. Paoni, Renhui Yang
-
Patent number: 5603783Abstract: A one-piece steering wheel is formed as a unitary casting from an alloy that includes 11.5% to 14% by weight silicon, and 350 to 450 parts per million strontium. Preferably the steering wheel mold is rotated during casting at relatively high rotational speeds exerting 100 g to 250 g force on the wheel. An optimum rotational speed is disclosed. A one-piece steering wheel formed according to the invention exhibits minimal length ferro-silicon hair-like strands, and thus exhibits reduced brittleness.Type: GrantFiled: June 21, 1994Date of Patent: February 18, 1997Assignee: M. J. Grootes Investments CCInventor: Cornelius J. T. Ferreira
-
Patent number: 5597798Abstract: The present invention comprises a method of sensitizing various types of cancer cells derived from different tissues of origin to various cytotoxic agents and augmenting the sensitivity of cancer cells to these cytotoxic agents. The invention provides a method to treat cancer and other cell proliferative diseases by the administration of a sensitizing agent prior to or concurrently with the administration of a cytotoxic agent.Type: GrantFiled: March 11, 1994Date of Patent: January 28, 1997Assignee: The Regents of the University of CaliforniaInventors: Stephen B. Howell, Randolph D. Christen, Seiji Isonishi, Paul A. Andrews
-
Patent number: 5595888Abstract: Provided are methods for the production of mixtures of interferon (IFN)-.gamma. polypeptides. The methods employ a single species of IFN-.sub..gamma. DNA having codons for Met-Gln and for residues 2-143 of the mature human IFN-.sub..gamma. amino acid sequence. Expression of such DNA in a suitable recombinant host cell affords a mixture of polypeptides having N-terminal Met-Gln, H-Gln, or H-pyroglutamate residues and C-termini at Arg.sup.139, Ser.sup.142, or Gln.sup.143 of the mature IFN-.sub..gamma. sequence. The polypeptides so produced exhibit the antiviral and antiproliferative activities as well as the acid lability characteristic of native human IFN-.sub..gamma..Type: GrantFiled: March 24, 1994Date of Patent: January 21, 1997Assignee: Genentech, Inc.Inventors: Patrick W. Gray, Ernst H. Rinderknecht
-
Patent number: 5593844Abstract: A ligand-mediated immunofunctional assay (LIFA) method for detecting the presence and the concentration of polypeptide hormone binding proteins which comprises capturing the binding protein with a solid phase bound first antibody, saturating the bound hormone binding protein with the ligand polypeptide hormone, and detecting the bound ligand polypeptide hormone with a detectably labeled second antibody specific for the ligand polypeptide hormone. In the absence of added saturating polypeptide hormone, the LIFA measures the amount of hormone binding protein bound to the endogenous ligand polypeptide hormone. A growth hormone binding protein assay illustrates the method of the present invention. LIFA assay results indicate that increased binding protein substantially increases growth hormone activity. Methods of use and formulations of growth hormone binding protein, growth hormone, insulin-like growth factor-I and insulin-like growth factor binding protein are disclosed.Type: GrantFiled: May 15, 1995Date of Patent: January 14, 1997Assignee: Genentech, Inc.Inventors: Lena M. S. Carlsson, Ross G. Clark, Wai L. T. Wong